Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 19/20 | 0.71 |
| ▸ | LITAF | Q99732 | 19/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24164971 | 1.00 | TNF (0.71) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL29385390 | 1.00 | TNF (0.71) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL30526900 | 1.00 | TNF (0.71) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL26145969 | 0.90 | TNF (0.88) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL29514464 | 0.90 | TNF (0.88) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL26145950 | 0.90 | TNF (0.88) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL29381799 | 0.90 | TNF (0.88) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL24164518 | 0.90 | TNF (0.88) | TNFLITAFPDE4BPDE4D | |
| SCHEMBL31355049 | 0.90 | TNF (0.88) | TNFLITAFPDE4BPDE4D | |
| Hydrochloric Acid SCHEMBL29384439 | 0.89 | TNF (0.86) | TNFLITAFPDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265089-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265089-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| CN-116529247-A | Crystal forms of hydrochloride of quinoline derivative | 维特卫治疗有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022005494-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265089-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | NQO2, STAT6, TPMT | TNF 133/4885LITAF 250/4885PDE4B 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.